Novo’s Weight Loss Drugs Removed from FDA Shortage List
The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk’s popular weight-loss and diabetes drugs, Wegovy and Ozempic, a declaration that will curtail widespread sales of cheaper copies made by compounding pharmacies.
Blockbuster weight-loss and diabetes drugs Wegovy and Ozempic are no longer in shortage, the US Food and Drug Administration ...
The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.
We will continue to offer access to personalized treatments as allowed by law to meet patient needs,” Hims & Hers CEO said.
The Food and Drug Administration on Friday announced that semaglutide, the active ingredient in weight loss drugs Ozempic and ...
ImmunityBio (IBRX) announced the U.S. Food and Drug Administration FDA has authorized an expanded access program EAP that will bring a vital ...
The FDA has authorized ImmunityBio’s expanded access program to bring alternative sources of the cancer-fighting bacteria BCG ...
The U.S., Uruguay, and Venezuela have the highest rates of gun-related suicides. The U.S. has almost double the number of gun ...
The total number of FDA positions eliminated remains unclear, but the firings appear to impact centers for food, medical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback